CA provides cancer care professionals with up-to-date information on all aspects of cancer diagnosis, treatment, and prevention. The journal focuses on keeping physicians and healthcare professionals informed by providing scientific and educational information in the form of comprehensive review articles and online continuing education activities on important cancer topics and issues that are important to cancer care, along with publishing the latest cancer guidelines and statistical articles from the American Cancer Society.
Edward L. Giovannucci, David M. Harlan, Michael C. Archer, Richard M. Bergenstal, Susan M. Gapstur, Laurel A. Habel, Michaël Pollak, Judith G. Regensteiner, Douglas Yee
Mahul B. Amin, Frederick L. Greene, Stephen B. Edge, Carolyn C. Compton, Jeffrey E. Gershenwald, Robert K. Brookland, Laura Meyer, Donna M. Gress, David R. Byrd, David P. Winchester
Andrew M. D. Wolf, Elizabeth T. H. Fontham, Timothy R. Church, Christopher R. Flowers, Carmen E. Guerra, Samuel J. LaMonte, Ruth Etzioni, Matthew T. McKenna, Kevin C. Oeffinger, Ya‐Chen Tina Shih, Louise C. Walter, Kimberly Andrews, Otis W. Brawley, Durado Brooks, Stacey A. Fedewa, Deana Manassaram‐Baptiste, Rebecca L. Siegel, Richard C. Wender, Robert A. Smith
Rebecca L. Siegel, Kimberly D. Miller, Ann Goding Sauer, Stacey A. Fedewa, Lynn F. Butterly, Joseph C. Anderson, Andrea Cercek, Robert A. Smith, Ahmedin Jemal
AbstractColorectal cancer (CRC) is the second most common cause of cancer death in the United States. Every 3 years, the American Cancer Society provides an update of CRC occurrence based on incidence data (available through 2016) from population‐based cancer registries and mortality data (through 2017) from the National Center for Health Statistics. In 2020, approximately 147,950 individuals will be diagnosed with CRC and 53,200 will die from the disease, including 17,930 cases and 3,640 deaths in individuals aged younger than 50 years. The incidence rate during 2012 through 2016 ranged from 30 (per 100,000 persons) in Asian/Pacific Islanders to 45.7 in blacks and 89 in Alaska Natives. Rapid declines in incidence among screening‐aged individuals during the 2000s continued during 2011 through 2016 in those aged 65 years and older (by 3.3% annually) but reversed in those aged 50 to 64 years, among whom rates increased by 1% annually. Among individuals aged younger than 50 years, the incidence rate increased by approximately 2% annually for tumors in the proximal and distal colon, as well as the rectum, driven by trends in non‐Hispanic whites. CRC death rates during 2008 through 2017 declined by 3% annually in individuals aged 65 years and older and by 0.6% annually in individuals aged 50 to 64 years while increasing by 1.3% annually in those aged younger than 50 years. Mortality declines among individuals aged 50 years and older were steepest among blacks, who also had the only decreasing trend among those aged younger than 50 years, and excluded American Indians/Alaska Natives, among whom rates remained stable. Progress against CRC can be accelerated by increasing access to guideline‐recommended screening and high‐quality treatment, particularly among Alaska Natives, and elucidating causes for rising incidence in young and middle‐aged adults.
Jason M. Foster, Chunmeng Zhang, Shahyan Rehman, Prateek Sharma, H. Richard Alexander
AbstractPeritoneal metastasis (PM) is often regarded as a less frequent pattern of spread; however, collectively across all spectra of primary tumors, the consequences of PM impact a large population of patients annually. Unlike other modes of metastasis, symptoms at presentation or during the treatment course are common, representing an additional challenge in the management of PM. Early efforts with chemotherapy and incomplete surgical interventions transiently improved symptoms, but durable symptom control and survival extension were rare, which established a perspective of treatment futility for PM through most of the 20th century. Notably, the continued development of better systemic therapy combinations, optimization of cytoreductive surgery (CRS), and rigorous investigation of combining regional therapy—specifically hyperthermic intraperitoneal chemotherapy—with CRS, have resulted in more effective multimodal treatment options for patients with PM. In this article, the authors provide a comprehensive review of the data establishing the contemporary approach for tumors with a high frequency of PM, including appendix, colorectal, mesothelioma, and gastric cancers. The authors also explore the emerging role of adding hyperthermic intraperitoneal chemotherapy to the well established paradigm of CRS and systemic therapy for advanced ovarian cancer, as well as the recent clinical trials identifying the efficacy of poly(adenosine diphosphate ribose) polymerase maintenance therapy. Finally, recent data are included that explore the role of precision medicine technology in PM management that, in the future, may help further improve patient selection, identify the best systemic therapy regimens, detect actionable mutations, and identify new targets for drug development.
Chỉ số ảnh hưởng
Total publication
26
Total citation
385,168
Avg. Citation
14,814.15
Impact Factor
0
H-index
26
H-index (5 years)
26
i10
26
i10-index (5 years)
3
Các tạp chí khác
Tạp chí Phụ Sản
Y Dược học cổ truyền Quân sự
Tạp chí Khoa học Xã hội và Nhân văn
Journal of International Economics and Management
Tạp chí Dinh dưỡng và Thực phẩm
Tạp chí Khoa học Đại học Đồng Tháp
Tạp chí Khoa học Kiểm sát
Tạp chí Khoa học Tự nhiên Đại học Quốc gia Thành phố Hồ Chí Minh
Tạp chí Khoa học Kiến trúc và Xây dựng
Tạp chí Nghiên cứu Khoa học và phát triển Trường Đại học Thành Đô